药代动力学
唑吡坦
最大值
医学
药效学
药理学
多导睡眠图
分配量
加药
催眠药
临床药理学
麻醉
失眠症
呼吸暂停
作者
Blumer Jl,MD Reed,Frank Steinberg,MaryAnn O’Riordan,CL Rosen,MA Springer,Michael Christensen,Daniel G. Glaze
标识
DOI:10.1038/sj.clpt.6100380
摘要
The pharmacokinetics of zolpidem was assessed in this open-label, dose-escalation study in children with insomnia. Twenty-one children, seven per age group (2-6, >6 to 12, >12 to 18 years), received a single dose of zolpidem at one of the three dose levels (0.125, 0.25, or 0.50 mg/kg (20 mg maximum dose)). Multiple pharmacokinetic measures were assessed at nine post-dose intervals and pharmacodynamics was assessed by polysomnography and actigraphy. Significant pharmacokinetic effects by dose were observed only as linear increases in maximum concentration (C(max), P<0.001) and area under the plasma concentration-time curve (AUC, P<0.001). Significant pharmacokinetic effects by age group included an increase in AUC (P=0.02), half-life (P=0.04), and mean residence time (P=0.01), whereas total body clearance decreased (P=0.01) and steady-state volume of distribution was variable. Pharmacodynamic measures were independent of the pharmacokinetic estimates. Overall, zolpidem was well tolerated and a pediatric dose of 0.25 mg/kg is recommended for future efficacy studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI